GlassScriptPhysician profile
Atul V Marathe
NPI 1326034695
$12,872.46
in general payments reported to CMS, 2019-2025
38 companies · $3,667 in 2025
The $3,667 reported for 2025 was more than what 89% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,119 · 2020: $471 · 2021: $703 · 2022: $1,693 · 2023: $2,127 · 2024: $3,093 · 2025: $3,667.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,868 · Education: $18.39.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,868.15 |
| Education | $18.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,250.80 | 2019-2025 | |
| Janssen Biotech, INC. | $1,446.28 | 2019-2025 | Tremfya, Stelara, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $990.38 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $755.64 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Pfizer INC. | $713.30 | 2019-2025 | |
| Ardelyx, INC. | $689.22 | 2022-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $564.90 | 2024-2025 | Rezdiffra, Resmetirom |
| Boston Scientific Corporation | $478.07 | 2019-2023 | |
| Celgene Corporation | $444.46 | 2023-2024 | Zeposia |
| Qol Medical, LLC | $401.56 | 2023-2025 | Sucraid, Sucraid |
| Phathom Pharmaceuticals, INC. | $397.78 | 2024-2025 | Voquezna |
| Genzyme Corporation | $389.04 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $357.21 | 2021-2024 | Zeposia |
| Lilly USA, LLC | $335.77 | 2024-2025 | Omvoh |
| Medtronic, INC. | $299.97 | 2021-2022 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Atul Marathe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.